Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C

Table 2 Analysis of factors affecting sustained virologic response in non-rapid virologic response hepatitis C virus genotype 2 patients treated with 36 or 48-wk pegylated interferon-α plus ribavirin combination therapy

	SVR	non-SVR	SVR vs non-SVR (1: non-SVR/2: SVR)
			Univaritate analysis	Multivaritate analysis
			P value	OR	95%CI	P value
Baseline factors
Demographic data
Number of patients	50	19
Gender (1:male/2:female)	20/30	11/8	0.2873
Age (yr)	60.5 (18-80)	53 (39-73)	0.2341
Body weight (kg)	55.0 (37.0-101.0)	64.0 (44.0-104.0)	0.1563
Body mass index (kg/m2)	22.8 (15.2-32.8)	22.8 (18.8-34.8)	0.2426
Histological fibrosis of liver (F0/1/2/3/4/ND)1	1/18/6/6/10/9	1/6/3/0/7/2
(F0-3/F4)	31/10	10/7	0.2050
Prior interferon and ribavirin treatment response
Naïve/Relapse/Non response	46/3/1	18/0/1	0.8933
Laboratory data
Genetic variation at rs8099917 (TG or GG/TT)	6/44	8/11	0.0146	5.87 (1; TG or GG/ 2; TT)	1.62-21.22	0.0059
HCV-RNA (Log10IU/mL)	6.3 (5.0-7.3)	6.4 (5.0-7.2)	0.6064
HCV Genotype (2a/2b/2a + 2b/ND)	21/24/2/3	8/10/0/1	0.8156
White blood cells (/μL)	4700 (2800-7800)	5550 (2000-10200)	0.3001
Hemoglobin (g/dL)	13.8 (11.0-16.9)	13.75 (11.0-16.8)	0.9279
Platelets (× 104/μL)	16.6 (6.0-34.1)	16.55 (6.1-29.7)	0.9834
Aspartate aminotransferase (IU/L)	54 (15-455)	32 (13-264)	0.0751
Alanine aminotransferase (IU/L)	59 (12-356)	36.5 (9-231)	0.1866
Gamma-glutamyl-transpeptitase (IU/L)	49 (9-292)	47 (11-331)	0.9237
Albumin (g/dL)	4.0 (2.9-4.8)	3.9 (3.1-4.7)	0.5738
Fasting total cholesterol (mg/dL)	172 (108-256)	178 (106-270)	0.6894
Fasting low density lipoprotein-cholesterol (mg/dL)	102 (54-177)	110 (40-181)	0.9647
Fasting plasma glucose (mg/dL)	98.5 (76-320)	103.5 (93-158)	0.1554
Homeostasis model assessment-Insulin Resistance	1.36 (0.78-6.78)	1.44 (1.19-5.39)	0.3151
Alpha-fetoprotein (ng/mL)	5.0 (1.0-96.0)	5.0 (2.0-130)	0.8593
On-treatment factors
Treatment
Adherence of Peg-IFN (%)2	77.1 (62.5-100.0)	91.4 (66.0-104.6)	0.0936
Adherence of RBV (%)2	75.0 (56.8-100.0)	86.1 (86.1-94.4)	0.0457
Duration of treatment (wk)	37 (36-48)	48 (36-48)	0.1449

¹Classified by METAVIR score;

²Calculated on the basis of 48-wk treatment. Note: Data are expressed as number of patients or median (range); ND: Not done; SVR: Sustained virologic response; HCV: Hepatitis C virus; Peg-IFN: Pegylated interferon; RBV: Ribavirin.